Audio

Anthony Reder, MD, Discusses a 21-Year Follow-Up Study of Patients Who Have Multiple Sclerosis

Neurology Reviews. 2012 July;20(7)

 

To read an accompanying article, please click here.

Recommended Reading

Jeffrey A. Cohen, MD, Describes His Comparison of Alemtuzumab and Interferon Beta-1a in Patients With Multiple Sclerosis
ICYMI Multiple Sclerosis
Laquinimod May Be Effective for the Long-Term Management of Multiple Sclerosis
ICYMI Multiple Sclerosis
Data Are Unclear About the Effectiveness of Laquinimod in Multiple Sclerosis—by Stuart Cook, MD
ICYMI Multiple Sclerosis
Tool Allows MS Patients to Assess How Their Impairment Compares to That of Other Patients With Same Disease Duration
ICYMI Multiple Sclerosis
Combined Use of Interferon beta-1a and Glatiramer Acetate May Not Be Superior to Glatiramer Acetate Alone in Reducing MS Relapses
ICYMI Multiple Sclerosis
New and Noteworthy Information—August
ICYMI Multiple Sclerosis
Long-Term Data Indicate Interferon Beta-1b Reduces the Risk of Death for Patients With MS
ICYMI Multiple Sclerosis
Interferon Beta May Not Reduce Disability Progression for Patients With MS
ICYMI Multiple Sclerosis
Should Patients Continue Natalizumab Treatment After a Positive JCV Test?
ICYMI Multiple Sclerosis
Cognitive Rehabilitation Improves Quality of Life in Patients With MS
ICYMI Multiple Sclerosis